Idexx Laboratories stock was rising sharply Monday, even as the S&P 500 and major indexes remained in the red. The Dow Jones ...
IDEXX Laboratories, Inc. IDXX posted fourth-quarter 2024 earnings per share (EPS) of $2.62, up 12.9% year over year. The ...
IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to ...
Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.
IDEXX Laboratories, Inc. (IDXX) is up by 11.55 percent during Friday morning trading, following the release of its fourth-quarter ...
Zacks.com on MSN18h
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat EstimatesIdexx (IDXX) delivered earnings and revenue surprises of 9.17% and 1.87%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IDEXX Laboratories, Inc. ( NASDAQ: IDXX) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & ...
Reports Q4 revenue $954M, consensus $936.68M. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams ...
Idexx forecast revenue between $4.06 billion and $4.17 billion in 2025, in line with analysts' estimates of $4.14 billion. The company also guided for earnings per share in the range of $11.74 and $12 ...
For the year, the company reported profit of $887.9 million, or $10.67 per share. Revenue was reported as $3.9 billion. Idexx expects full-year earnings to be $11.74 to $12.24 per share, with revenue ...
IDEXX Laboratories Inc (NASDAQ:IDXX) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback